PDRN for Hair Regrowth
Evidence Review created on 08/02/2026 using AI4L + evidence-mcp / Opus 4.8
Also known as: Polydeoxyribonucleotide, Polynucleotides, PN, Placentex, Salmon DNA Injection
Motivation
Polydeoxyribonucleotide (PDRN) is a mixture of small DNA fragments, most often purified from salmon sperm, that is injected into the scalp or skin to encourage tissue repair. Once used mainly to speed wound healing, it has become a popular regenerative treatment in cosmetic clinics, where it is now being tried as a way to thicken thinning hair.
Hair thinning affects a large share of adults, and the two long-standing treatments — one applied to the scalp and one taken by mouth — do not help everyone and can cause unwanted effects. This has driven interest in gentler, follicle-supporting options. Early clinics report that a short series of scalp injections can improve hair density and shaft thickness, frequently used alongside conventional therapies rather than in place of them.
This review examines what is currently known about PDRN for hair regrowth: how it is thought to work, what the available studies do and do not show, its safety profile, and the practical details of how it is used. It presents the evidence as it stands, including its important gaps.
Benefits - Risks - Protocol - Conclusion
Recommended Reading
A curated set of high-level overviews and key primary studies that introduce PDRN and its use for hair regrowth.
-
From Polydeoxyribonucleotides (PDRNs) to Polynucleotides (PNs): Bridging the Gap Between Scientific Definitions, Molecular Insights, and Clinical Applications of Multifunctional Biomolecules - Marques et al., 2025
A comprehensive narrative review that clarifies the often-confused distinction between PDRN and higher-weight polynucleotides, and maps their shared mechanisms and clinical uses. It is the single best orientation to what PDRN actually is before evaluating the hair-specific evidence.
-
Polynucleotides and polydeoxyribonucleotides in dermatology – A narrative review - Arora, 2026
A dermatology-focused overview covering pharmacology, sourcing, indications (including a scalp/hair-loss injection protocol), and evidence gaps. Useful for readers who want a clinician’s synthesis rather than a single trial.
-
Polynucleotides as a novel therapeutic approach in androgenetic alopecia: an analysis of effectiveness and safety - Thanasarnaksorn et al., 2025
A prospective study of 28 pattern-hair-loss patients treated with four polynucleotide injection sessions, reporting improvements in hair diameter and density with no serious side effects. It is among the most directly on-topic recent clinical reports.
-
Therapeutic efficacy of autologous platelet-rich plasma and polydeoxyribonucleotide on female pattern hair loss - Lee et al., 2015
One of the earliest controlled comparisons isolating PDRN’s effect on hair, showing gains in hair count and thickness both alone and combined with platelet-rich plasma. It remains a frequently cited reference point for the PDRN-alone signal.
-
The efficacy of polynucleotide injections in aesthetic medicine: a review - Matin Ahmadi
An accessible practitioner-oriented review of polynucleotide injectables across aesthetic indications, giving practical context on protocols, expectations, and tolerability that carries over to scalp use.
Note: No qualifying content on PDRN or polynucleotides for hair was found from the priority experts listed above; the selection instead draws on peer-reviewed reviews, primary clinical studies, and a practitioner journal.
Grokipedia
-
Polynucleotides in aesthetic medicine
This dedicated page describes injectable polynucleotides and PDRN as salmon-DNA-derived regenerative treatments, covering their biostimulatory mechanism and cosmetic uses including scalp and hair applications. It provides a concise lay-level entry point that complements the clinical literature.
Examine
No Examine article exists for PDRN. Examine.com focuses on orally ingested dietary supplements and nutrients and does not typically cover prescription or clinic-administered aesthetic injectables such as PDRN.
ConsumerLab
No ConsumerLab article exists for PDRN. ConsumerLab.com independently tests dietary supplements sold to consumers and does not cover injectable prescription or clinic-administered products such as PDRN.
Systematic Reviews
The following systematic reviews and meta-analyses evaluate PDRN and polynucleotides; because no hair-specific systematic review or meta-analysis has yet been published, they cover the closest aesthetic and regenerative indications and establish the quality of the broader PDRN evidence base.
-
The Effectiveness of Polynucleotides in Esthetic Medicine: A Systematic Review - Lampridou et al., 2025
Synthesizes nine studies (219 patients) on polynucleotide injections in aesthetic medicine, finding promising but low-to-moderate-quality evidence and calling for rigorous trials. It is the most relevant systematic review to the hair/scalp use case, though it centers on skin rejuvenation.
-
The efficacy and safety of polydeoxyribonucleotide for the treatment of knee osteoarthritis: Systematic review and meta-analysis of randomized controlled trials - Kim et al., 2019
A meta-analysis of five randomized controlled trials showing PDRN injections match hyaluronic acid on function and outperform it on short-term pain, with comparable safety. It is one of the few PDRN meta-analyses built on randomized data, useful for gauging effect quality.
-
Does polydeoxyribonucleotide has an effect on patients with tendon or ligament pain?: A PRISMA-compliant meta-analysis - Gwak et al., 2021
Pools one randomized trial and three observational studies, finding significant pain reduction after PDRN injection for tendon/ligament disorders. It illustrates both PDRN’s regenerative signal and the field’s reliance on small, mixed-quality studies.
-
Polydeoxyribonucleotide in the Treatment of Tendon Disorders, from Basic Science to Clinical Practice: A Systematic Review - Bizzoca et al., 2023
Bridges the mechanistic (adenosine A2A receptor, salvage pathway) and clinical evidence for PDRN in tendon repair. It is a helpful model for how PDRN’s biology is argued to translate into tissue regeneration relevant to the follicle.
-
Efficacy of Polydeoxyribonucleic Acid (PDRN) in periodontal regeneration: A systematic review of clinical outcomes - Mari et al., 2025
Reviews PDRN’s regenerative performance in periodontal (gum and bone) tissue, another soft-tissue regeneration setting. It reinforces the recurring theme of encouraging early signals limited by small samples and heterogeneous protocols.
Mechanism of Action
PDRN is a mixture of low-molecular-weight DNA fragments (roughly 50–1,500 base pairs) purified from the sperm or gonads of salmonid fish such as salmon (Oncorhynchus) and rainbow trout (Oncorhynchus mykiss). It is proposed to support hair regrowth through two complementary routes, neither of which targets the male hormone pathway that drives pattern hair loss.
-
Adenosine A2A receptor activation: PDRN is broken down by enzymes into nucleosides and bases, and the adenosine released activates the A2A adenosine receptor (a cell-surface switch that dampens inflammation and triggers new blood-vessel formation). In the scalp this is thought to reduce the low-grade inflammation around miniaturizing follicles and raise local levels of VEGF (vascular endothelial growth factor, a signal that spurs new blood-vessel growth), improving the follicle’s blood and nutrient supply.
-
The salvage pathway: PDRN also feeds the “salvage pathway,” an energy-saving route by which cells recycle ready-made nucleotides and bases to build new DNA instead of making them from scratch. By supplying these building blocks, PDRN is proposed to boost the proliferation of dermal papilla cells and keratinocytes (the follicle’s growth-driving and hair-shaft-producing cells), helping keep follicles in their active growth phase.
Higher-molecular-weight polynucleotides (PN) — frequently marketed for hair under the same umbrella — are believed to act more as a hydrating, biostimulating scaffold in addition to the salvage pathway, whereas PDRN’s lower-weight fragments act more directly via the adenosine receptor. This distinction is often blurred in marketing, and many “PDRN hair” products are in fact PN.
- Competing mechanistic view: A skeptical interpretation holds that any observed benefit may owe less to PDRN’s specific biology than to the injection process itself. Needle micro-injury (as in microneedling) and the accompanying wound-healing response can independently stimulate follicles, so PDRN’s separate contribution above needling and combination agents such as platelet-rich plasma remains difficult to isolate from current data.
Key pharmacological properties (characterized mainly for injectable PDRN/Placentex): a short plasma half-life of roughly 3 hours with pharmacodynamic effects lasting longer; high bioavailability after intramuscular injection; broad tissue distribution favoring well-vascularized tissue; degradation by plasma and membrane-bound nucleases (DNA-cutting enzymes) rather than liver metabolism; and elimination that is largely renal (about two-thirds in urine). It is not metabolized through the cytochrome P450 liver-enzyme system, which limits classic drug–drug interactions.
Historical Context & Evolution
-
Original intended use: PDRN originated as a tissue-repair and wound-healing agent. DNA-derived injectable preparations were developed decades ago (the branded product Placentex was originally derived from human placenta before shifting to fish-sourced DNA), and PDRN became established for indications such as diabetic foot ulcers, skin grafts, and burns, where its pro-angiogenic and anti-inflammatory actions speed healing.
-
Move into regenerative and aesthetic medicine: Because the same actions that heal wounds — new blood-vessel growth, fibroblast stimulation, and reduced inflammation — also underlie skin quality and tissue rejuvenation, PDRN and polynucleotides migrated into aesthetic practice for skin “biorevitalization.” Products such as Rejuran (Korea) and Plinest/Newest (Europe) popularized salmon-DNA injectables for skin, and clinicians then extended the same logic to the scalp, reasoning that a better-vascularized, less-inflamed follicular environment should support hair growth.
-
What the early hair research showed: The first dedicated hair study (Lee and colleagues, 2015) compared PDRN alone against PDRN combined with platelet-rich plasma in female pattern hair loss and documented measurable gains in hair count and thickness in both groups, with an accompanying animal experiment showing upregulation of growth-related signaling (WNT and growth-factor pathways). Subsequent small prospective studies of polynucleotide injections reported similar density and thickness improvements. These findings established a plausible signal rather than definitive proof.
-
Evolution of scientific opinion: Opinion has moved from initial enthusiasm toward cautious interest. Systematic reviews of polynucleotides in aesthetic medicine now emphasize that, despite consistent positive reports, the underlying studies are small, heterogeneous, and often lack robust controls — so the current standing is “promising and biologically plausible, but not yet validated by high-quality hair-specific trials.” This is a live, evolving area rather than a settled question, and new randomized data could strengthen or weaken the case.
Expected Benefits
Benefits are framed for a proactive, health-focused adult considering PDRN as part of a hair-optimization plan. Because dedicated hair evidence is limited to small studies, no benefit reaches the High or Medium tiers.
Low 🟩
Increased Hair Density
The most consistently reported benefit is a rise in the number of hairs per unit area of scalp. The proposed mechanism is improved follicular blood supply and reduced perifollicular inflammation, which can help miniaturizing follicles recover and dormant follicles re-enter growth. Evidence comes from small prospective studies and a controlled comparison in female pattern hair loss; there are no large randomized trials, and several studies combine PDRN with other treatments, limiting certainty.
Magnitude: Roughly +18% mean hair count with PDRN alone (and up to about +23% when combined with platelet-rich plasma) over ~3 months in a small controlled study; other prospective series report significant density gains from about one month onward.
Increased Hair Shaft Thickness
PDRN is reported to increase the diameter (caliber) of individual hair shafts, making existing hair appear fuller. This aligns with a shift of follicles from a miniaturized toward a healthier growth state driven by better local nutrition and growth-factor signaling. As with density, the supporting studies are small and often combine PDRN with platelet-rich plasma or other modalities.
Magnitude: Approximately +13% to +17% mean hair thickness over ~3 months in a small controlled study; combination with platelet-rich plasma produced greater thickness gains than PDRN alone.
Value as an Add-On to Existing Therapy
PDRN’s follicle-supporting, non-hormonal action makes it attractive as an add-on to standard treatments (topical minoxidil, oral finasteride, platelet-rich plasma, or microneedling) rather than a replacement. Because it works through a different route than androgen-pathway drugs, it may complement them without overlapping side effects. Evidence for additive benefit is suggestive — combination arms tend to outperform single agents — but has not been rigorously quantified in hair.
Magnitude: Not quantified in available studies.
Speculative 🟨
Reduced Perifollicular Inflammation and Improved Scalp Quality
Beyond counted hairs, PDRN may improve the overall scalp environment by calming the chronic low-grade inflammation (“microinflammation”) implicated in pattern hair loss and by enhancing skin hydration and vascularity, as seen in aesthetic skin studies. The basis here is mechanistic and extrapolated from skin-rejuvenation data rather than measured directly in scalp trials, so it remains speculative for hair.
Benefit in Non-Androgenetic or Refractory Alopecia
Because PDRN’s regenerative action is not androgen-specific, it has been proposed for hair loss types where hormone-blocking drugs do not apply — such as telogen effluvium (temporary stress- or illness-related shedding), scarring alopecias, or thinning in patients who have not responded to conventional therapy. Support is limited to isolated reports and mechanistic reasoning, with no controlled data in these settings, so this is speculative.
Benefit-Modifying Factors
-
Genetic polymorphisms: No PDRN-specific pharmacogenetic variants are known. However, the severity and pattern of the underlying androgenetic alopecia (pattern hair loss, influenced by androgen receptor and other susceptibility genes) affect how much regrowth is realistically achievable — heavily miniaturized or long-dormant follicles respond less than early-stage thinning.
-
Baseline biomarker levels: Correctable deficiencies that independently impair hair growth — low iron stores (ferritin), low vitamin D, or thyroid imbalance — can blunt the apparent benefit of PDRN if left unaddressed. Optimizing these before or alongside treatment gives PDRN a better substrate to work on.
-
Sex-based differences: PDRN and polynucleotides have shown density and thickness gains in both female pattern hair loss and male pattern hair loss; the earliest controlled hair data are in women. There is no clear evidence that one sex responds substantially better, but women more often use PDRN because oral hormone-blocking options are less suitable for them.
-
Pre-existing health conditions: Better outcomes are expected in follicles that are still viable. Scarring (cicatricial) alopecia, longstanding complete baldness, and active scalp inflammation or infection reduce the likelihood of meaningful response; well-controlled early-to-moderate thinning responds best.
-
Age-related considerations: Younger adults with recent-onset thinning and preserved follicles tend to respond better than older adults at the upper end of the target range, in whom prolonged follicle miniaturization and reduced regenerative capacity limit achievable regrowth.
Potential Risks & Side Effects
PDRN is generally regarded as well tolerated; its risks are mostly local and procedure-related, and no serious systemic adverse events have been reported in the small hair studies to date.
High 🟥 🟥 🟥
Injection-Site Reactions
Transient pain, redness (erythema), swelling, tenderness, small bruises, and pinpoint bleeding at the scalp injection sites are the most common effects, reflecting the mechanical trauma of multiple micro-injections rather than the compound itself. They typically resolve within hours to a few days. Severity depends on technique, needle depth, and the number of injection points; the scalp is relatively sensitive, so discomfort during treatment is expected.
Magnitude: Very common; mild and self-limited in essentially all reported cases, usually resolving within 1–3 days.
Low 🟥
Nodules, Papules, or Lumpiness
Small palpable nodules or papules can form when injected material is deposited too superficially or unevenly, or as a localized reaction to the product. These are usually temporary and resolve as the material disperses, but they can occasionally persist for weeks. Careful injection technique and appropriate depth reduce the risk.
Magnitude: Uncommon; typically transient, resolving over days to a few weeks.
Infection and Injection-Related Complications
Any injection through the skin carries a small risk of introducing bacteria, leading to local infection, folliculitis, or (rarely) abscess. Bloodstream-related complications and vascular injury are theoretically possible but very rare with superficial scalp mesotherapy. Sterile technique and trained administration are the main safeguards.
Magnitude: Not quantified in available studies.
Hypersensitivity / Allergic Reaction
Because PDRN is derived from fish DNA, allergic reactions are a theoretical concern, particularly in people with fish allergy. In practice, high-grade purification removes most protein allergens and reactions are rarely reported, but localized allergic responses cannot be excluded. Prior patch testing can be considered in allergy-prone individuals.
Magnitude: Not quantified in available studies.
Speculative 🟨
Unknown Long-Term Safety
There are no long-term safety data for repeated scalp PDRN over years, and follow-up in existing studies is short (months). While the mechanism gives no specific reason to expect delayed harm, the absence of long-term surveillance means rare or cumulative effects cannot be ruled out.
Theoretical Concerns in Special Populations
PDRN has not been studied in pregnancy or breastfeeding, and its regenerative, pro-angiogenic action has not been evaluated for interaction with active malignancy or autoimmune scalp disease. These concerns are precautionary and mechanistic rather than based on observed adverse outcomes.
Risk-Modifying Factors
-
Genetic polymorphisms: No genetic variants are known to modify PDRN’s risk profile. Known fish-allergy predisposition is the closest relevant factor and relates to hypersensitivity risk rather than a specific polymorphism.
-
Baseline biomarker levels: People on blood-thinning medication or with clotting abnormalities (which may be reflected in coagulation labs or a low platelet count) are more prone to bruising and bleeding from the multiple injections. Poorly controlled blood sugar (a high HbA1c, the marker of average blood sugar over about three months) can raise local infection risk.
-
Sex-based differences: No meaningful sex-based difference in PDRN side effects has been established; injection-site reactions occur similarly in men and women. Cosmetic sensitivity to transient bruising may matter more for some individuals regardless of sex.
-
Pre-existing health conditions: Active scalp infection, dermatitis, or open lesions increase the risk of spreading infection and are reasons to defer treatment. Immunosuppression and poorly controlled diabetes raise infection risk; bleeding disorders raise bruising risk.
-
Age-related considerations: Older adults more often take anticoagulant or antiplatelet drugs and may have thinner, more fragile scalp skin, modestly increasing bruising and slower healing at injection sites; this is a tolerability consideration rather than a serious safety concern.
Key Interactions & Contraindications
-
Prescription drug interactions: PDRN has no known systemic pharmacokinetic drug interactions because it is not metabolized by the liver and acts largely locally. The main clinically relevant interaction is with anticoagulants and antiplatelet agents (warfarin, direct oral anticoagulants such as apixaban and rivaroxaban, clopidogrel), which increase injection-site bruising and bleeding. Severity: caution; consequence: increased bruising/hematoma. Mitigation: review bleeding risk, consider timing around dosing, apply firm post-injection pressure.
-
Over-the-counter medication interactions: Aspirin and non-steroidal anti-inflammatory drugs (NSAIDs, over-the-counter pain relievers such as ibuprofen and naproxen) can increase bruising and bleeding at injection sites. Severity: caution; consequence: increased bruising. Mitigation: where medically appropriate, avoid non-essential NSAIDs/aspirin for several days before treatment.
-
Supplement interactions: Supplements with blood-thinning or antiplatelet effects — high-dose fish oil (omega-3s), vitamin E, ginkgo, garlic, and ginger — can add to bruising risk from the injections. Severity: caution; consequence: increased bruising. Mitigation: consider pausing high-dose blood-thinning supplements around the procedure.
-
Additive (potentiating) combinations: PDRN is commonly and deliberately combined with treatments that support hair through complementary routes — platelet-rich plasma, microneedling, topical minoxidil, and oral finasteride. These are intended additive combinations rather than harmful interactions; the main caution is compounding injection-related bruising when stacked with other injectables on the same day.
-
Other intervention interactions: Scheduling PDRN close to other scalp procedures (laser, strong chemical exfoliation, or hair transplantation) requires spacing to allow the scalp to recover; combining multiple aggressive procedures at once increases irritation and infection risk. Severity: caution; consequence: cumulative scalp irritation/delayed healing. Mitigation: separate procedures by appropriate intervals per practitioner guidance.
-
Populations who should avoid or defer treatment: Pregnant or breastfeeding women (no safety data); people with known fish/seafood allergy (hypersensitivity risk); those with active scalp infection, inflammation, or open wounds at the treatment site; individuals with uncontrolled bleeding disorders or thrombocytopenia (platelet count meaningfully below the normal range, e.g. <50,000/µL); people on high-intensity anticoagulation with unstable control; and those with active scalp skin cancer or undiagnosed scalp lesions. Severity ranges from absolute contraindication (active local infection, pregnancy given absent data) to caution (managed anticoagulation).
Risk Mitigation Strategies
-
Use a trained injector with sterile technique: Have PDRN administered only by a qualified clinician using aseptic preparation and single-use sterile needles, to prevent infection, folliculitis, and abscess — the main serious (if rare) injection risks. This directly mitigates injection-related infection.
-
Screen and manage bleeding risk before treatment: Review anticoagulant, antiplatelet, and blood-thinning supplement use; where medically appropriate, pause non-essential NSAIDs, aspirin, high-dose fish oil, and vitamin E for roughly 3–7 days beforehand, and apply firm post-injection pressure and cold compresses. This mitigates bruising, hematoma, and prolonged bleeding.
-
Confirm allergy history and consider patch testing: Ask specifically about fish and seafood allergy before the first session and consider a small test dose or patch test in allergy-prone individuals, to reduce the chance of a hypersensitivity reaction to the salmon-derived product.
-
Optimize injection depth and volume to avoid nodules: Ensure even, appropriately deep intradermal/subcutaneous placement and avoid over-injecting a single point, which prevents palpable nodules, papules, and surface lumpiness.
-
Defer treatment when the scalp is not healthy: Postpone sessions during active scalp infection, dermatitis, sunburn, or open lesions, and space PDRN at least 1–2 weeks from other aggressive scalp procedures, to prevent infection spread and cumulative irritation or delayed healing.
-
Set realistic expectations and correct underlying drivers: Address iron, vitamin D, and thyroid status and continue proven therapies where indicated, so that PDRN is not relied upon alone; this mitigates the risk of treatment “failure,” wasted cost, and abandoning effective standard care.
Therapeutic Protocol
-
Standard induction protocol: As used by leading aesthetic and hair-restoration clinicians, PDRN/polynucleotides are delivered by intradermal or subcutaneous scalp injection (scalp mesotherapy) across the thinning areas. A typical course is an induction phase of about 3–4 sessions spaced 2–4 weeks apart, followed by maintenance. Published hair studies have used regimens ranging from four sessions at four-week intervals to a more intensive weekly series.
-
Maintenance: After induction, maintenance sessions are commonly repeated every 3–6 months to sustain results, since the effect is not permanent and the underlying pattern hair loss continues.
-
Competing therapeutic approaches: A conventional-first approach prioritizes evidence-backed minoxidil and finasteride, adding PDRN only as an adjunct; a regenerative/integrative approach foregrounds injectables (PDRN, polynucleotides, platelet-rich plasma) with microneedling, often for patients seeking drug-free or add-on options. Neither is presented here as the default — the regenerative route has weaker evidence but a different risk profile, and the two are frequently combined.
-
Popularizing experts and products: Korean regenerative dermatology (via salmon-DNA products such as Rejuran) and European aesthetic clinics (via Plinest/Newest and Placentex from manufacturers such as Mastelli) drove adoption; the first controlled hair-specific protocol was reported by Lee and colleagues in female pattern hair loss.
-
Best time of day: Timing of day is not clinically relevant for PDRN, as it acts locally at the follicle with no known circadian or systemic dependence; sessions are scheduled for convenience.
-
Half-life and dosing frequency (single vs split): The injectable compound has a short plasma half-life (~3 hours) but longer-lasting tissue effects, which is why benefit depends on a repeated series of sessions rather than a single treatment; each session’s dose is distributed (“split”) across many small injection points over the scalp rather than delivered at one site.
-
Genetic considerations: No pharmacogenetic testing guides PDRN dosing. Genotype matters only indirectly through the severity of the underlying androgenetic alopecia, which informs whether PDRN is used alone or alongside androgen-pathway drugs.
-
Sex-based differences in protocol: Protocols are broadly similar for men and women; the practical difference is that women, who often cannot use oral finasteride, more frequently use PDRN as a core add-on to minoxidil, whereas men more often layer it onto finasteride plus minoxidil.
-
Age-related considerations: Older adults at the upper end of the target range may need clearer expectation-setting (less regenerative reserve) and attention to anticoagulant use and skin fragility, but the core injection schedule is unchanged.
-
Baseline biomarker considerations: Practitioners typically check and correct ferritin, vitamin D, and thyroid status before or during a course, since these influence how well follicles can respond to any hair therapy.
-
Pre-existing condition considerations: Follicle viability guides candidacy — early-to-moderate, non-scarring thinning with active follicles is the best target; scarring alopecia and complete baldness are poor candidates.
Discontinuation & Cycling
-
Lifelong vs short-term: PDRN is best understood as an ongoing maintenance treatment, not a one-time cure. It does not alter the hormonal driver of pattern hair loss, so gains achieved during an induction course tend to fade over months once treatment stops.
-
Withdrawal effects: There are no pharmacological withdrawal effects from stopping PDRN — no dependence, rebound shedding, or discontinuation syndrome is expected. What occurs is a gradual return toward the untreated trajectory as the regenerative stimulus is no longer renewed.
-
Tapering: No tapering is required; PDRN can be stopped abruptly without physiological consequence. In practice, rather than tapering, clinicians move from the closely spaced induction phase to less frequent maintenance sessions.
-
Cycling: Formal cycling (planned on/off periods) is not established or necessary for efficacy. The prevailing pattern is an intensive induction phase followed by periodic maintenance, which functions as a de-escalation rather than a cycle; there is no evidence that scheduled breaks preserve or enhance response.
Sourcing and Quality
-
Source and origin: PDRN and polynucleotide products are derived from purified salmonid fish DNA (commonly salmon Oncorhynchus or trout sperm/gonads). Quality hinges on the purification process, which must remove proteins, peptides, and endotoxins so that mainly the DNA fragments remain; poorly purified material carries higher immunogenicity and contamination risk.
-
What to look for: Prefer products from established manufacturers with a documented purification standard and, where applicable, regulatory clearance as a medical device (for example, a CE mark in Europe or approval by the relevant national authority). Look for stated DNA concentration and fragment characteristics, sterile single-use packaging, and administration by a licensed clinic — not unregulated or grey-market vials.
-
PDRN vs polynucleotide formulations: Because “PDRN” is often used loosely, verify whether a product is genuinely low-weight PDRN or a higher-weight polynucleotide (PN), as these differ in molecular size and intended action. Some hair products also combine the DNA fraction with hyaluronic acid; the specific formulation affects viscosity, injection technique, and marketing claims.
-
Reputable products/brands: Recognized names in this category include Placentex (PDRN, Mastelli), Plinest and Newest (polynucleotides), and Rejuran (salmon-DNA polynucleotide); these are examples of established medical-grade lines rather than endorsements, and availability and regulatory status vary by country.
-
Avoiding topical/counterfeit confusion: A wave of over-the-counter “PDRN” cosmetics (serums, ampoules, sheet masks) uses low-cost or plant-/microbe-derived PDRN at low concentrations and cannot be assumed to match the injectable evidence; buyers should distinguish clinic-administered injectables from topical consumer products making similar-sounding claims.
Practical Considerations
-
Time to effect: Early changes in shaft thickness and density are often reported from about one month after starting, with more visible improvement accumulating over roughly 3–6 months as the injection series progresses; PDRN is not an overnight fix and requires completing the course.
-
Common pitfalls: Frequent mistakes include expecting a single session to work, stopping after induction without maintenance, using PDRN as a standalone substitute for proven minoxidil/finasteride in advanced loss, treating scarred or long-dead follicles that cannot respond, neglecting to correct iron/vitamin D/thyroid deficiencies, and buying topical consumer “PDRN” products expecting injection-level results.
-
Regulatory status: In most markets PDRN/polynucleotide injectables are regulated as medical devices or drugs for skin/tissue indications, and their use for hair regrowth is off-label; they are not approved by the US Food and Drug Administration for hair loss, and availability differs widely by country. This off-label status means the treatment is offered privately rather than as a standard-of-care prescription.
-
Cost and accessibility: PDRN scalp treatment is an out-of-pocket cosmetic expense requiring repeated clinic visits, so the cumulative cost over an induction-plus-maintenance year can be substantial and is generally not covered by insurance; access depends on finding a qualified clinic offering it, which is more common in Europe and East Asia than in some other regions.
Interaction with Foundational Habits
-
Sleep: Direction — indirect/neutral. PDRN has no systemic or stimulant action and is not expected to disrupt or improve sleep. The indirect link is that adequate sleep supports overall tissue repair and hormonal balance, which underpins the follicular environment PDRN aims to enhance; no timing precautions are needed.
-
Nutrition: Direction — indirect/potentiating. PDRN itself supplies nucleotide building blocks locally and does not deplete nutrients, but its benefit can be limited by systemic deficiencies. Ensuring adequate protein, iron (correcting low ferritin), zinc, and vitamin D provides the raw materials and metabolic conditions for follicles to respond; there are no specific foods to avoid, and no fasting requirement around treatment.
-
Exercise: Direction — indirect/neutral. There is no evidence that exercise blunts or enhances PDRN, and no need to time workouts around sessions. The only practical note is that vigorous exercise immediately after injections may increase transient scalp flushing or sweating over fresh injection sites, so a brief pause on the treatment day is reasonable for comfort and hygiene.
-
Stress management: Direction — indirect/potentiating. Chronic stress can trigger or worsen shedding (telogen effluvium) and sustain the low-grade inflammation implicated in hair loss. Managing stress is complementary to PDRN’s anti-inflammatory, follicle-supporting aim; while no direct effect on cortisol is claimed for PDRN, reducing a stress-driven shedding stimulus improves the odds that regrowth efforts hold.
Monitoring Protocol & Defining Success
Before starting, a baseline assessment establishes the type and severity of hair loss and rules out correctable systemic contributors; this is done through scalp/hair evaluation plus targeted blood tests rather than any PDRN-specific test. Ongoing monitoring is primarily visual and trichological: standardized global photographs and dermoscopic (magnified scalp) hair-count/diameter measurements at baseline, then at roughly 3 months, 6 months, and every 6 months thereafter, with blood markers rechecked as clinically indicated.
-
Baseline labs and tests: Standardized clinical photographs; dermoscopy/trichoscopy for hair density and shaft caliber; and the blood panel below to detect deficiencies that impair hair growth.
-
Ongoing labs and tests: Repeat photographs and dermoscopy to track density and thickness on the cadence above; recheck ferritin, vitamin D, and thyroid function if they were abnormal at baseline or if response is poor.
| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|---|---|---|---|
| Ferritin | 40–70 ng/mL or higher | Iron store status; low iron impairs hair growth and mimics/worsens shedding | Conventional “normal” starts far lower (~15–30 ng/mL), so a value called normal can still be too low for hair; ferritin rises with inflammation, so pair with CRP (C-reactive protein) if inflammation is suspected |
| Vitamin D (25-OH) | 40–60 ng/mL | Follicle cycling support; deficiency is linked to several hair-loss types | 25-OH means 25-hydroxyvitamin D, the standard storage form measured; conventional sufficiency is often set lower (>20–30 ng/mL); no fasting required |
| TSH | 0.5–2.0 mIU/L | Detects thyroid dysfunction, a common reversible cause of diffuse thinning | TSH means thyroid-stimulating hormone; conventional labs flag only outside ~0.4–4.5; add free T4/T3 if abnormal; best drawn in the morning |
| Zinc | 90–135 µg/dL | Zinc deficiency contributes to hair loss and impairs tissue repair | Serum zinc is an imperfect marker; draw fasting and avoid supplements immediately before testing for accuracy |
| Total Testosterone & DHT | Sex- and age-appropriate reference range | Context for androgen-driven pattern loss, especially in women with signs of hormonal imbalance | DHT means dihydrotestosterone, the potent androgen that drives follicle miniaturization; order selectively (e.g., women with irregular cycles or signs of excess androgens), drawn in the morning |
-
Qualitative markers:
- Reduced daily shedding (fewer hairs on pillow/in shower/drain)
- Subjective scalp coverage and fullness
- Ease of styling and less visible scalp
- Personal/photographic satisfaction over months
Success is best defined conservatively: stabilization of loss and a measurable increase in density and shaft caliber on standardized photos and dermoscopy over 6 months, rather than dramatic regrowth. Because pattern hair loss is progressive, holding ground counts as a meaningful result.
Emerging Research
Research framed for a proactive reader tracking whether PDRN will earn a validated place in hair care — including studies that could strengthen or weaken the case.
-
No hair-specific registered trials yet: As of August 2026, a search of ClinicalTrials.gov returned no registered interventional trials evaluating PDRN or polynucleotides specifically for hair regrowth or alopecia. This registry gap is itself notable and is a key reason the current hair evidence rests on small single-center studies.
-
Adjacent regenerative/aesthetic trials in progress: NCT07151859 — a recruiting clinical investigation of a polynucleotide-based device for skin hydration and elasticity (sponsor Mastelli; ~43 participants), relevant because it tests the same salmon-DNA biostimulation in skin. NCT07472192 — a recruiting Phase 2 study of PDRN combined with fractional carbon-dioxide laser versus laser alone for facial scar remodeling (~36 participants), informative on PDRN’s added regenerative value when combined with a needling/ablative stimulus.
-
Isolating PDRN from combination and needling effects: A priority is disentangling PDRN’s specific contribution from platelet-rich plasma, microneedling, and standard drugs. The controlled comparison by Lee et al., 2015 began this by testing PDRN alone versus PDRN plus platelet-rich plasma; larger randomized designs with sham-needling controls could either confirm an independent effect or attribute results to the procedure — a finding that would weaken the case.
-
Head-to-head trials against standard therapy: No study has compared PDRN directly with minoxidil or finasteride. Randomized non-inferiority or add-on trials versus these standards would define whether PDRN is a genuine option or a costly adjunct; the prospective signal reported by Thanasarnaksorn et al., 2025 motivates such trials.
-
Standardization and evidence-quality upgrades: Systematic reviewers have flagged small samples, heterogeneous protocols, and PDRN/PN conflation as the central weaknesses (Lampridou et al., 2025; Marques et al., 2025). Future work standardizing molecular definitions, dose, and endpoints — and reporting long-term follow-up — will determine whether the encouraging early signal survives rigorous testing.
Conclusion
PDRN is a salmon-derived DNA fragment injected into the scalp to support the hair follicle rather than to block the hormones that drive pattern hair loss. Its proposed value lies in calming inflammation around the follicle, improving local blood supply, and providing raw materials that help follicle cells renew themselves. Because it works differently from the established treatments, interest centers on using it as an add-on rather than a replacement.
The evidence remains early and thin. The studies available so far are small, mostly lack rigorous comparison groups, and often combine PDRN with other treatments, which makes its independent contribution hard to isolate. Within those limits, they point in a consistent and encouraging direction — modest gains in hair density and thickness over a few months, with a treatment that is generally well tolerated apart from the expected discomfort of scalp injections. Long-term results and direct comparisons with standard therapies are largely missing, and much of the research comes from the companies and clinics that provide the treatment.
For a health-focused reader weighing a regenerative, relatively low-risk addition to a hair program, PDRN is a plausible but unproven option whose promise currently outpaces the strength of the evidence behind it.